PortalPublikationenA transient early HBV DNA increase during PEG-IFNα therapy o...

A transient early HBV DNA increase during PEG-IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV RNA and HBsAg reduction

Standard

A transient early HBV DNA increase during PEG-IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV RNA and HBsAg reduction. / Anastasiou, Olympia E; Yurdaydin, Cihan; Maasoumy, Benjamin; Hardtke, Svenja; Alexandru Caruntu, Florin; Curescu, Manuela G; Yalcin, Kendal; Akarca, Ulus S; Gürel, Selim; Zeuzem, Stefan; Erhardt, Andreas; Lüth, Stefan; Papatheodoridis, George V; Radu, Monica; Liebig, Stephanie; Bantel, Heike; Bremer, Birgit; Manns, Michael P; Cornberg, Markus; Wedemeyer, Heiner.

in: J VIRAL HEPATITIS, Jahrgang 28, Nr. 2, 02.2021, S. 410-419.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Anastasiou, OE, Yurdaydin, C, Maasoumy, B, Hardtke, S, Alexandru Caruntu, F, Curescu, MG, Yalcin, K, Akarca, US, Gürel, S, Zeuzem, S, Erhardt, A, Lüth, S, Papatheodoridis, GV, Radu, M, Liebig, S, Bantel, H, Bremer, B, Manns, MP, Cornberg, M & Wedemeyer, H 2021, 'A transient early HBV DNA increase during PEG-IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV RNA and HBsAg reduction', J VIRAL HEPATITIS, Jg. 28, Nr. 2, S. 410-419. https://doi.org/10.1111/jvh.13439

APA

Anastasiou, O. E., Yurdaydin, C., Maasoumy, B., Hardtke, S., Alexandru Caruntu, F., Curescu, M. G., Yalcin, K., Akarca, U. S., Gürel, S., Zeuzem, S., Erhardt, A., Lüth, S., Papatheodoridis, G. V., Radu, M., Liebig, S., Bantel, H., Bremer, B., Manns, M. P., Cornberg, M., & Wedemeyer, H. (2021). A transient early HBV DNA increase during PEG-IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV RNA and HBsAg reduction. J VIRAL HEPATITIS, 28(2), 410-419. https://doi.org/10.1111/jvh.13439

Vancouver

Anastasiou OE, Yurdaydin C, Maasoumy B, Hardtke S, Alexandru Caruntu F, Curescu MG et al. A transient early HBV DNA increase during PEG-IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV RNA and HBsAg reduction. J VIRAL HEPATITIS. 2021 Feb;28(2):410-419. https://doi.org/10.1111/jvh.13439

Bibtex

@article{061bef23de2745118b46e3c7ee629f67,
title = "A transient early HBV DNA increase during PEG-IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV RNA and HBsAg reduction",
abstract = "HBV-DNA levels are low or even undetectable in the majority HDV-infected patients. The impact of PEG-IFNα on HBV-DNA kinetics in HDV-infected patients has not been studied in detail. We analysed data of a prospective treatment trial where 120 HDV-RNA-positive patients were randomized to receive PEG-IFNα-2a plus tenofovir-disoproxil-fumarate (PEG-IFNα/TDF, n = 59) or placebo (PEG-IFNα/PBO; n = 61) for 96 weeks. At week 96, HBV-DNA was still quantifiable in 71% of PEG-IFNα/PBO-treated patients but also in 76% of PEG-IFNα/TDF-treated patients, despite low HBV-DNA baseline values. Surprisingly, a transient HBV-DNA increase between weeks 12 and 36 was observed in 12 in PEG-IFNα/TDF-treated and 12 PEG-IFNα/PBO-treated patients. This increase was positively associated with HBsAg loss [(P = 0.049, odds ratio (OR) 5.1] and HDV-RNA suppression (P = 0.007, OR 4.1) at week 96. Biochemical markers of cell death (M30 and ALT) were higher during the HBV-DNA peak but no distinct systemic immune pattern could be observed by screening 91 soluble inflammatory markers. In conclusion, an early increase in HBV-DNA during PEG-IFNα-2a therapy occurred in more than 20% of patients, even in TDF-treated patients. This transient HBV-DNA rise may indicate PEG-IFNα-induced cell death and lead to long-term HDV-RNA suppression and HBsAg loss.",
author = "Anastasiou, {Olympia E} and Cihan Yurdaydin and Benjamin Maasoumy and Svenja Hardtke and {Alexandru Caruntu}, Florin and Curescu, {Manuela G} and Kendal Yalcin and Akarca, {Ulus S} and Selim G{\"u}rel and Stefan Zeuzem and Andreas Erhardt and Stefan L{\"u}th and Papatheodoridis, {George V} and Monica Radu and Stephanie Liebig and Heike Bantel and Birgit Bremer and Manns, {Michael P} and Markus Cornberg and Heiner Wedemeyer",
note = "{\textcopyright} 2020 John Wiley & Sons Ltd.",
year = "2021",
month = feb,
doi = "10.1111/jvh.13439",
language = "English",
volume = "28",
pages = "410--419",
journal = "J VIRAL HEPATITIS",
issn = "1352-0504",
publisher = "Wiley-Blackwell",
number = "2",

}

RIS

TY - JOUR

T1 - A transient early HBV DNA increase during PEG-IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV RNA and HBsAg reduction

AU - Anastasiou, Olympia E

AU - Yurdaydin, Cihan

AU - Maasoumy, Benjamin

AU - Hardtke, Svenja

AU - Alexandru Caruntu, Florin

AU - Curescu, Manuela G

AU - Yalcin, Kendal

AU - Akarca, Ulus S

AU - Gürel, Selim

AU - Zeuzem, Stefan

AU - Erhardt, Andreas

AU - Lüth, Stefan

AU - Papatheodoridis, George V

AU - Radu, Monica

AU - Liebig, Stephanie

AU - Bantel, Heike

AU - Bremer, Birgit

AU - Manns, Michael P

AU - Cornberg, Markus

AU - Wedemeyer, Heiner

N1 - © 2020 John Wiley & Sons Ltd.

PY - 2021/2

Y1 - 2021/2

N2 - HBV-DNA levels are low or even undetectable in the majority HDV-infected patients. The impact of PEG-IFNα on HBV-DNA kinetics in HDV-infected patients has not been studied in detail. We analysed data of a prospective treatment trial where 120 HDV-RNA-positive patients were randomized to receive PEG-IFNα-2a plus tenofovir-disoproxil-fumarate (PEG-IFNα/TDF, n = 59) or placebo (PEG-IFNα/PBO; n = 61) for 96 weeks. At week 96, HBV-DNA was still quantifiable in 71% of PEG-IFNα/PBO-treated patients but also in 76% of PEG-IFNα/TDF-treated patients, despite low HBV-DNA baseline values. Surprisingly, a transient HBV-DNA increase between weeks 12 and 36 was observed in 12 in PEG-IFNα/TDF-treated and 12 PEG-IFNα/PBO-treated patients. This increase was positively associated with HBsAg loss [(P = 0.049, odds ratio (OR) 5.1] and HDV-RNA suppression (P = 0.007, OR 4.1) at week 96. Biochemical markers of cell death (M30 and ALT) were higher during the HBV-DNA peak but no distinct systemic immune pattern could be observed by screening 91 soluble inflammatory markers. In conclusion, an early increase in HBV-DNA during PEG-IFNα-2a therapy occurred in more than 20% of patients, even in TDF-treated patients. This transient HBV-DNA rise may indicate PEG-IFNα-induced cell death and lead to long-term HDV-RNA suppression and HBsAg loss.

AB - HBV-DNA levels are low or even undetectable in the majority HDV-infected patients. The impact of PEG-IFNα on HBV-DNA kinetics in HDV-infected patients has not been studied in detail. We analysed data of a prospective treatment trial where 120 HDV-RNA-positive patients were randomized to receive PEG-IFNα-2a plus tenofovir-disoproxil-fumarate (PEG-IFNα/TDF, n = 59) or placebo (PEG-IFNα/PBO; n = 61) for 96 weeks. At week 96, HBV-DNA was still quantifiable in 71% of PEG-IFNα/PBO-treated patients but also in 76% of PEG-IFNα/TDF-treated patients, despite low HBV-DNA baseline values. Surprisingly, a transient HBV-DNA increase between weeks 12 and 36 was observed in 12 in PEG-IFNα/TDF-treated and 12 PEG-IFNα/PBO-treated patients. This increase was positively associated with HBsAg loss [(P = 0.049, odds ratio (OR) 5.1] and HDV-RNA suppression (P = 0.007, OR 4.1) at week 96. Biochemical markers of cell death (M30 and ALT) were higher during the HBV-DNA peak but no distinct systemic immune pattern could be observed by screening 91 soluble inflammatory markers. In conclusion, an early increase in HBV-DNA during PEG-IFNα-2a therapy occurred in more than 20% of patients, even in TDF-treated patients. This transient HBV-DNA rise may indicate PEG-IFNα-induced cell death and lead to long-term HDV-RNA suppression and HBsAg loss.

U2 - 10.1111/jvh.13439

DO - 10.1111/jvh.13439

M3 - SCORING: Journal article

C2 - 33185325

VL - 28

SP - 410

EP - 419

JO - J VIRAL HEPATITIS

JF - J VIRAL HEPATITIS

SN - 1352-0504

IS - 2

ER -